AP2A1
AP-2 complex subunit alpha-1
Also known as: ADTAA, AP2A1_HUMAN, CLAPA1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O95782
- Gene
- AP2A1
- Ensembl
- ENSG00000196961
- Chromosome
- 19
- Canonical length
- 977 aa
- Protein class
- Predicted intracellular proteins, Transporters
- Subcellular location
- Vesicles
OverviewNCBI Gene
This gene encodes the alpha 1 adaptin subunit of the adaptor protein 2 (AP-2) complex found in clathrin coated vesicles. The AP-2 complex is a heterotetramer consisting of two large adaptins (alpha or beta), a medium adaptin (mu), and a small adaptin (sigma). The complex is part of the protein coat on the cytoplasmic face of coated vesicles which links clathrin to receptors in vesicles. Alternative splicing of this gene results in two transcript variants encoding two different isoforms. A third transcript variant has been described, but its full length nature has not been determined. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
977 residues, UniProt reviewed canonical sequence.
>O95782|AP2A1
1 MPAVSKGDGM RGLAVFISDI RNCKSKEAEI KRINKELANI RSKFKGDKAL DGYSKKKYVC
61 KLLFIFLLGH DIDFGHMEAV NLLSSNKYTE KQIGYLFISV LVNSNSELIR LINNAIKNDL
121 ASRNPTFMCL ALHCIANVGS REMGEAFAAD IPRILVAGDS MDSVKQSAAL CLLRLYKASP
181 DLVPMGEWTA RVVHLLNDQH MGVVTAAVSL ITCLCKKNPD DFKTCVSLAV SRLSRIVSSA
241 STDLQDYTYY FVPAPWLSVK LLRLLQCYPP PEDAAVKGRL VECLETVLNK AQEPPKSKKV
301 QHSNAKNAIL FETISLIIHY DSEPNLLVRA CNQLGQFLQH RETNLRYLAL ESMCTLASSE
361 FSHEAVKTHI DTVINALKTE RDVSVRQRAA DLLYAMCDRS NAKQIVSEML RYLETADYAI
421 REEIVLKVAI LAEKYAVDYS WYVDTILNLI RIAGDYVSEE VWYRVLQIVT NRDDVQGYAA
481 KTVFEALQAP ACHENMVKVG GYILGEFGNL IAGDPRSSPP VQFSLLHSKF HLCSVATRAL
541 LLSTYIKFIN LFPETKATIQ GVLRAGSQLR NADVELQQRA VEYLTLSSVA STDVLATVLE
601 EMPPFPERES SILAKLKRKK GPGAGSALDD GRRDPSSNDI NGGMEPTPST VSTPSPSADL
661 LGLRAAPPPA APPASAGAGN LLVDVFDGPA AQPSLGPTPE EAFLSELEPP APESPMALLA
721 DPAPAADPGP EDIGPPIPEA DELLNKFVCK NNGVLFENQL LQIGVKSEFR QNLGRMYLFY
781 GNKTSVQFQN FSPTVVHPGD LQTQLAVQTK RVAAQVDGGA QVQQVLNIEC LRDFLTPPLL
841 SVRFRYGGAP QALTLKLPVT INKFFQPTEM AAQDFFQRWK QLSLPQQEAQ KIFKANHPMD
901 AEVTKAKLLG FGSALLDNVD PNPENFVGAG IIQTKALQVG CLLRLEPNAQ AQMYRLTLRT
961 SKEPVSRHLC ELLAQQFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against AP2A1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 85 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 85 nTPM
- testis: 85 nTPM
- adrenal gland: 84 nTPM
- cerebral cortex: 79 nTPM
- cerebellum: 68 nTPM
- ovary: 55 nTPM
Single-cell type
- syncytiotrophoblasts: 355 nCPM
- late spermatids: 222 nCPM
- cytotrophoblasts: 137 nCPM
- early spermatids: 133 nCPM
- late primary spermatocytes: 120 nCPM
- erythrocyte progenitors: 117 nCPM
Immune cell
- non-classical monocyte: 21 nTPM
- intermediate monocyte: 13 nTPM
- classical monocyte: 5.3 nTPM
- total PBMC: 4.8 nTPM
- myeloid DC: 4.7 nTPM
- neutrophil: 4 nTPM
Brain region
- thalamus: 150 nTPM
- cerebral cortex: 145 nTPM
- pons: 139 nTPM
- amygdala: 123 nTPM
- hippocampal formation: 119 nTPM
- basal ganglia: 119 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.1
- gnomAD pLI
- 1
- gnomAD missense Z
- 4.4
- DepMap mean gene effect
- -0.03
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- clathrin-dependent endocytosis
- endocytosis
- Golgi to endosome transport
- intracellular protein transport
- negative regulation of hyaluronan biosynthetic process
- positive regulation of neuron projection development
- positive regulation of receptor-mediated endocytosis
- postsynaptic neurotransmitter receptor internalization
- synaptic vesicle endocytosis
- vesicle-mediated transport
Molecular functions
- clathrin adaptor activity
- low-density lipoprotein particle receptor binding
- protein kinase binding
- protein-containing complex binding
Cellular components
- AP-2 adaptor complex
- apical plasma membrane
- basolateral plasma membrane
- clathrin coat of trans-Golgi network vesicle
- clathrin-coated endocytic vesicle
- clathrin-coated endocytic vesicle membrane
- cytoplasmic side of plasma membrane
- cytosol
- endocytic vesicle membrane
- endolysosome membrane
- filopodium tip
- glutamatergic synapse
- membrane
- plasma membrane
- postsynaptic endocytic zone
- synaptic vesicle
Protein domainsUniProt · Pfam · InterPro
- Clathrin/coatomer adaptor, adaptin-like, N-terminal
- Clathrin adaptor, alpha-adaptin, appendage, C-terminal subdomain
- Clathrin adaptor, alpha/beta/gamma-adaptin, appendage, Ig-like subdomain
- Coatomer/calthrin adaptor appendage, C-terminal subdomain
- Armadillo-like helical
- TBP domain superfamily
- Clathrin adaptor, appendage, Ig-like subdomain superfamily
- Armadillo-type fold
- Adaptor protein complex AP-2, alpha subunit
- Adaptor Complexes Large Subunit
- Adaptin N terminal region
- Alpha adaptin AP2, C-terminal domain
- Adaptin C-terminal domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of AP2A1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads AP2A1 as an antibody target. Whether an autoantibody or antibody against AP2A1 could matter depends on whether native AP2A1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
AP2A1 is annotated at the cell surface, where native AP2A1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label AP2A1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...